Request a copy

Full Text

• Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 2008, 113:1980-1993.
• Bosch FX, Lorincz A, Munoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
• Koss LG. The Papanicolaou test for cervical cancer detection: a triumph and a tragedy. JAMA 1989, 261:737-743.
• Arbyn M, Bergeron C, Klinkhammer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and metaanalysis. Obstet Gynecol 2008, 111:167-177.
• European guidelines for quality assurance in cervical cancer screening 2008, 1-291. Arbyn MAnttila AJordan JRonco GSchenck USegnan NWiener HDaniel Jvon Karsa L. 2nd, edn, eds, Luxembourg, Office for Official Publications of the European Communities, pp
• http://www.has-sante.fr, Agence Nationale d'Accréditation et d'Evaluation en Santé (ANAES) - Service des recommandations professionnelles - Service évaluation économique: conduite à tenir devant une patiente ayant un frottis cervico-utérin anormal. Actualisation 2002.
• Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000, 92:397-402.
• Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. ASCCP-Sponsored Consensus Conference 2001. Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002, 287:2120-2129.
• Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004, 96:280-293.
• Arbyn M, Sasieni P, Meijer CJLM, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006, 24S3:79-89. S3
• de RodaHusman AM, Walboomers JMM, van denBrule AJC, Meijer JC, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by polymerase chain reaction. J Gen Virol 1995, 76:1057-1062.
• Clavel C, Masure M, Putaud I. Hybrid Capture II, a new sensitive test for human papillomavirus detection: comparison with Hybrid capture I and PCR results in cervical lesions. J Clin Pathol 1998, 51:737-740.
• Jacobs MV, Snijders PJF, vandenBrule AJC, Helmershorst TJM, Meijer CJLM, Walboomers JMM. A general primer GP5+/GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J.Clin Microbiol 1997, 35:791-795.
• Davis-Devine S, Day SJ, Freund GG. Test performance comparison of inform HPV and hybrid capture 2 high-risk HPV DNA tests using the SurePath liquid-based Pap test as the collection method. Am J Clin Pathol 2005, 124:24-30.
• Kapala J, Jang D, Patel J, Biers K, Smieja M, Chernesky M. Pap cytopathology and the presence of high-risk human papillomavirus in SurePath liquid preservative and Digene cervical sampler specimens. J Virol Methods 2007, 142:223-225.
• Jastania R, Geddie WR, Chapman W, Boerner S. Characteristics of apparently false-negative Digene Hybrid Capture 2 high-risk HPV DNA Testing. Am J Clin Pathol 2006, 125:223-228.
• Weynand B, Berlière M, Haumont E. ThermoShandon's Papspin: a new, liquid-based cytology technique. Acta Cytol 2003, 47:149-153.
• Bozzetti M, Nonnenmacher B, Mielzinska I. Comparison between Hybrid Capture II and polymerase chain reaction results among women at low-risk for cervical cancer. Ann Epidemiol 2000, 10:466.
• Clavel C, Masure M, Bory JP. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer 1999, 80:1306-1311.
• Peyton CL, Schiffman M, Lörincz AT. Comparison of PCR- and Hybrid Capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol 1998, 36:3248-3254.
• Szostek S, Klimek M, Zawilinska B, Rys J, Kopec J, Daszkiewicz E. Detection of human papillomavirus in cervical cell specimens by hybrid capture and PCR with different primers. Acta Biochim Pol 2006, 53:603-607.
• de Crémoux P, Coste J, Sastre-Garau X. Efficiency of the Hybrid Capture 2 HPV DNA test in cervical cancer screening. A study of the French Society of Clinical Cytology. Am J Clin Pathol 2003, 120:492-499. the French Society of Clinical Cytology Study Group
• Huang SL, Chao A, Hsueh S. Comparison between the Hybrid Capture II test and an SPF1/GP6 PCR-based assay for the detection of human papillomavirus DNA in cervical swab samples. J Clin Microbiol 2006, 44:1733-1739.
• Kulmala SM, Syrjänen S, Shabalova I. Human papillomavirus testing with the Hybrid Capture 2 assay and PCR as screening tools. J Clin Microbiol 2004, 42:2470-2475.
• Manavi M, Bauer M, Pischinger K, Czerwenka K. Detection of human papillomavirus on Papanicolaou-stained cervical smears using indirect in situ polymerase chain reaction hybridization. Arch Pathol Lab Med 2001, 125:353-357.
• Ho GY, Burk RD, Klein S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995, 87:1365-1371.
• Schlecht NF, Platt RW, Duarte-Franco E. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003, 95:1336-1343.
• Woodman CB, Collins S, Winter H. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001, 357:1831-1836.